Oxford, UK, 30th September 2019 – Celleron Therapeutics, the UK-based clinical stage biotech company developing personalised medicines for cancer patients, today announced that it is presenting a Phase II clinical trial data at ESMO 2019. The Phase II clinical trial…
Oxford, UK, 6 August 2019 – Celleron Therapeutics, the UK-based clinical stage biotech company developing personalised medicines for cancer patients, today announced that it will participate and present  phase II trial data at ESMO 2019 in Spain. The Phase II…
Oxford, UK, 17 Jun 2019 – Celleron Therapeutics, a UK-based company developing personalised medicines for cancer patients, announced today approval by a Data and Safety Monitoring Committee for continuation of  the UK Phase II clinical trial (CAROSELL) testing the  immune-oncology…
Oxford UK, 15 June 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today that its Founding Director and Chief Medical Officer Professor David Kerr presented at the 15th Shanghai International Colorectal Cancer Symposium. Professor…
Oxford, UK, 22 May 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, participated in the China session of the 20th BioEquity Europe Conference, held in Barcelona, Spain on 20-21 May 2019. China: An R&D Hot…
Oxford, UK, 16 April 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today the successful proof-of-concept efficacy read-out from their UK Phase II clinical trial, testing the immune-oncology agent nivolumab in combination with their…
Oxford, UK, 21 March 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announce today a new UK Phase Ib/II clinical trial testing a novel immune-oncology agent in combination with its novel epigenetic regulator CXD101, in…
Oxford, UK, 16 March 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, held a cake sale at its Head Office in Oxford in support of Comic Relief’s Red Nose Day. A day of fundraising including…
The investment will advance Argonaut’s Therapeutics’ arginine methylation inhibitor drug candidate towards the clinic and enable continued expansion of its drug discovery pipeline. Oxford, UK, March 2019 – Argonaut Therapeutics, a leading developer of novel cancer therapies, announced that it…
Oxford, UK, February 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, on World Cancer Day affirms its commitment to start clinical trials in 2019 of new treatments for a variety of cancers Celleron Therapeutics is…